New treatment options may make "no evidence of disease activity" (NEDA: no relapses or disability progression and no new/enlarging MRI lesions, as opposed to "evidence of disease activity" (EDA) with at least one of the former), an achievable goal in relapsing-remitting multiple sclerosis (RRMS). The objective of the present study was to determine whether early RRMS patients with EDA at one-yea...

Background Evolution of gadolinium-enhancing lesions into chronic black holes (CBH) may be reduced by interferon (IFN) therapy. Objective The objective of this paper is to assess the effect of IFN β-1a and placebo on CBH evolution and disability in patients with relapsing-remitting multiple sclerosis (RRMS), as well as CBH evolution in patients with secondary progressive multiple sclerosis (S...

BACKGROUND Sleep disturbances in multiple sclerosis (MS) have received little research attention despite the potential influence it may have on the impact of the disease. The aim of this study was to evaluate the prevalence of sleep disturbances in a Lithuanian community sample of individuals with the relapsing remitting multiple sclerosis (RRMS) and its relation with depression, anxiety, and h...

The regulatory role of interleukin-35 (IL-35) in the immunopathogenesis of multiple sclerosis (MS) is suggested in very few studies. We aimed to measure serum levels of IL-35 among clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients and evaluate the associations between this cytokine and the disease clinical course. This cross-sectional study was conducted during 2017 ...

This study aimed to investigate the relationship between chronic fatigue syndrome (CFS) and depression with the mediating role of executive functions (EFs) in patients with relapsing-remitting multiple sclerosis (RRMS). The statistical population of this descriptive correlational study included all patients with RRMS who were referred to Tehran neurologists in the summer of 2021 and among them,...

Background: We aim to identify differentially expressed genes (DEGs) and its pathways associated with clinical activity of relapsing–remitting Multiple Sclerosis (RRMS). Methods: We screened DEG in blood samples from patients with clinically stable or active RRMS (≥2 relapses or increase in ≥1 point in the EDSS (due to relapses) in 2 years follow-up), and healthy controls using DNA arrays. The ...

BACKGROUND Gray matter atrophy has been implicated in the development of secondary progressive multiple sclerosis (SPMS). Cortical function may be assessed by transcranial magnetic stimulation (TMS). Determining whether cortical dysfunction was a feature of SPMS could be of pathophysiological significance. OBJECTIVES Consequently, novel paired-pulse threshold tracking TMS techniques were used...

Over the past 25 years, monoclonal antibodies (mAb) have become important elements in the therapeutic concepts for numerous clinical specialities, including oncology, gastroenterology, hemostaseology and endocrinology. One of the most dynamic fields of their use is the treatment of autoimmune diseases. Although the number of existing mAb interfering with the immune system has increased remarkab...

Abstract Background Multiple sclerosis is a chronic demyelinating disease of the central nervous system. It may lead to disability and cognitive impairment. Our study aimed at evaluation role MR volumetry technique in detection brain atrophic changes patients with multiple its impact on prognosis. Results This was carried out thirty healthy control mean age 26.23 years remitting relapsing scler...

As one of the most common neurological disabilities in young adults, Multiple sclerosis (MS) has characteristics of inflammation, demyelination, neuro-axonal damage, and progressive prolonged disability. The disease is clinically divided into three general categories according to response to treatment: Relapsing-Remitting MS (RRMS), Primary Progressive MS (PPMS) and Secondary Progressive MS (SP...